Clinuvel Pharmaceuticals Ltd - Asset Resilience Ratio
Clinuvel Pharmaceuticals Ltd (CUV) has an Asset Resilience Ratio of 86.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Clinuvel Pharmaceuticals Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Clinuvel Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See net assets of Clinuvel Pharmaceuticals Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Clinuvel Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CUV market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$36.14 Million | 13.4% |
| Short-term Investments | AU$196.86 Million | 72.99% |
| Total Liquid Assets | AU$233.00 Million | 86.39% |
Asset Resilience Insights
- Very High Liquidity: Clinuvel Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 86.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Clinuvel Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Clinuvel Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Clinuvel Pharmaceuticals Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Clinuvel Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 72.16% | AU$196.09 Million ≈ $138.74 Million |
AU$271.75 Million ≈ $192.28 Million |
+7.83pp |
| 2024-06-30 | 64.32% | AU$148.67 Million ≈ $105.19 Million |
AU$231.12 Million ≈ $163.53 Million |
-4.02pp |
| 2023-06-30 | 68.34% | AU$132.95 Million ≈ $94.07 Million |
AU$194.52 Million ≈ $137.64 Million |
+3.36pp |
| 2022-06-30 | 64.98% | AU$94.10 Million ≈ $66.58 Million |
AU$144.81 Million ≈ $102.47 Million |
+23.02pp |
| 2021-06-30 | 41.96% | AU$45.55 Million ≈ $32.23 Million |
AU$108.57 Million ≈ $76.82 Million |
-8.44pp |
| 2020-06-30 | 50.40% | AU$41.09 Million ≈ $29.08 Million |
AU$81.54 Million ≈ $57.70 Million |
+4.64pp |
| 2019-06-30 | 45.75% | AU$28.52 Million ≈ $20.18 Million |
AU$62.35 Million ≈ $44.11 Million |
+0.14pp |
| 2018-06-30 | 45.61% | AU$19.57 Million ≈ $13.85 Million |
AU$42.90 Million ≈ $30.36 Million |
+12.26pp |
| 2017-06-30 | 33.35% | AU$9.54 Million ≈ $6.75 Million |
AU$28.61 Million ≈ $20.24 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$20.14 Million ≈ $14.25 Million |
-- |
| 2012-06-30 | 2.84% | AU$453.60K ≈ $320.95K |
AU$16.00 Million ≈ $11.32 Million |
-23.55pp |
| 2011-06-30 | 26.39% | AU$5.32 Million ≈ $3.76 Million |
AU$20.17 Million ≈ $14.27 Million |
+0.67pp |
| 2010-06-30 | 25.72% | AU$7.59 Million ≈ $5.37 Million |
AU$29.51 Million ≈ $20.88 Million |
-12.84pp |
| 2009-06-30 | 38.55% | AU$16.04 Million ≈ $11.35 Million |
AU$41.61 Million ≈ $29.44 Million |
-7.01pp |
| 2008-06-30 | 45.57% | AU$25.05 Million ≈ $17.72 Million |
AU$54.97 Million ≈ $38.90 Million |
+3.53pp |
| 2007-06-30 | 42.04% | AU$28.51 Million ≈ $20.17 Million |
AU$67.82 Million ≈ $47.99 Million |
+30.18pp |
| 2006-06-30 | 11.86% | AU$2.02 Million ≈ $1.43 Million |
AU$17.07 Million ≈ $12.08 Million |
-- |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more